Newborn Screening for Fabry Disease: Current Status of Knowledge
International Journal of Neonatal Screening · 05.06.2023 · 9 (2) · 31
DOI: 10.3390/ijns9020031 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 05.06.2023. Verfasst von Vincenza Gragnaniello und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, 35128 Padua, Italy. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fabry disease is an X-linked progressive lysosomal disorder, due to α-galactosidase A deficiency. Patients with a classic phenotype usually present in childhood as a multisystemic disease. Patients presenting with the later onset subtypes have cardiac, renal and neurological involvements in adulthood. Unfortunately, the diagnosis is often delayed until the organ damage is already irreversibly severe, making specific treatments less efficacious. For this reason, in the last two decades, newborn screening has been implemented to allow early diagnosis and treatment. This became possible with the application of the standard enzymology fluorometric method to dried blood spots. Then, high-throughput multiplexable assays, such as digital microfluidics and tandem mass spectrometry, were developed. Recently DNA-based methods have been applied to newborn screening in some countries. Using these methods, several newborn screening pilot studies and programs have been implemented worldwide. However, several concerns persist, and newborn screening for Fabry disease is still not universally accepted. In particular, enzyme-based methods miss a relevant number of affected females. Moreover, ethical issues are due to the large number of infants with later onset forms or variants of uncertain significance. Long term follow-up of individuals detected by newborn screening will improve our knowledge about the natural history of the disease, the phenotype prediction and the patients’ management, allowing a better evaluation of risks and benefits of the newborn screening for Fabry disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital, 35128 Padua, Italy.
- Neurology Unit, St Bassiano Hospital, 36061 Bassano del Grappa, Italy.
ORCID-Profile: Alessandro P Burlina, Elena Porcù, Alberto B Burlina
Zitieren
APA
Gragnaniello, V., Burlina, A. P., Commone, A., Gueraldi, D., Puma, A., Porcù, E., Stornaiuolo, M., Cazzorla, C., & Burlina, A. B. (2023). Newborn Screening for Fabry Disease: Current Status of Knowledge. International Journal of Neonatal Screening, 9(2), 31. https://doi.org/10.3390/ijns9020031
Vancouver
Gragnaniello V, Burlina AP, Commone A, Gueraldi D, Puma A, Porcù E, et al. Newborn Screening for Fabry Disease: Current Status of Knowledge. International Journal of Neonatal Screening. 2023;9(2):31. doi:10.3390/ijns9020031
BibTeX
@article{Gragnaniello2023,
author = {Gragnaniello, Vincenza and Burlina, Alessandro P and Commone, Anna and Gueraldi, Daniela and Puma, Andrea and Porcù, Elena and Stornaiuolo, Maria and Cazzorla, Chiara and Burlina, Alberto B},
title = {Newborn Screening for Fabry Disease: Current Status of Knowledge},
journal = {International Journal of Neonatal Screening},
year = {2023},
volume = {9},
number = {2},
pages = {31},
doi = {10.3390/ijns9020031}
}
EUVIMED